-
Thematic Analysis
NewGlobal Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Analyst Opinions
NewDecarbonizing Maritime and Aviation Overview by Key Energy Transition Technologies and Case Studies, 2024 Update
Decarbonizing Maritime and Aviation Market Report Overview The automotive sector experiences a strong growth in demand for electric vehicles. However, the aviation and maritime sectors have been slow to decarbonize. To incentivize emission reductions, both sectors have set bold net-zero targets. However, according to the IEA, the sectors remain disoriented. Demand for cost-competitive and energy-dense fuels has led aviation and maritime to represent two of the most difficult to abate sectors. Both sectors will likely need to engage with a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07264660 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07264660 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07264660 in Atopic Dermatitis (Atopic Eczema) Drug Details: PF-07264660 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Gastric Cancer Drug Details: MEDI-5752 is under development for the treatment of solid...
-
Product Insights
Retinopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinopathy - Drugs In Development, 2023’, provides an overview of the Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pre-Eclampsia – Drugs In Development, 2023
Global Markets Direct’s, ‘Pre-Eclampsia - Drugs In Development, 2023’, provides an overview of the Pre-Eclampsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...